Evidence map›Paper›PMID 31187896›Full record

ReviewComprehensive Physiology2019

Tissue Engineering of the Microvasculature.

Joe Tien

Open access · greenAbstract readReview
In one paragraph

Review in Comprehensive Physiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Vascularization strategies in tissue engineering approaches for soft tissue repair.Journal of tissue engineering and regenerative medicine · 2021
    Review
  11. Review
  12. Review
  13. Microfluidic Biomaterials.Advanced healthcare materials · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Joe TienDepartment of Biomedical Engineering, Boston University, Boston, Massachusetts, USA.
University of Massachusetts Boston · US

Funding

Engineered Invasive Human Breast Tumors with Integrated Capillaries and LymphaticsU01CA214292 · NCI · BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · PI NELSON, CELESTE M, TIEN, JOE Y · 2017 to 2021
$3.2M
(Re)vascularization of decellularized scaffoldsR03EB024660 · NIBIB · BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · PI TIEN, JOE Y · 2017 to 2018
$165k
NCI NIH HHS U01 CA214292NIBIB NIH HHS R03 EB024660
6 · The paper itself

Abstract

The ability to generate new microvessels in desired numbers and at desired locations has been a long-sought goal in vascular medicine, engineering, and biology. Historically, the need to revascularize ischemic tissues nonsurgically (so-called therapeutic vascularization) served as the main driving force for the development of new methods of vascular growth. More recently, vascularization of engineered tissues and the generation of vascularized microphysiological systems have provided additional targets for these methods, and have required adaptation of therapeutic vascularization to biomaterial scaffolds and to microscale devices. Three complementary strategies have been investigated to engineer microvasculature: angiogenesis (the sprouting of existing vessels), vasculogenesis (the coalescence of adult or progenitor cells into vessels), and microfluidics (the vascularization of scaffolds that possess the open geometry of microvascular networks). Over the past several decades, vascularization techniques have grown tremendously in sophistication, from the crude implantation of arteries into myocardial tunnels by Vineberg in the 1940s, to the current use of micropatterning techniques to control the exact shape and placement of vessels within a scaffold. This review provides a broad historical view of methods to engineer the microvasculature, and offers a common framework for organizing and analyzing the numerous studies in this area of tissue engineering and regenerative medicine. © 2019 American Physiological Society. Compr Physiol 9:1155-1212, 2019.

Indexed as

Angiogenesis Inducing AgentsAnimalsClinical Trials as TopicDisease Models, AnimalDrug Delivery SystemsGenetic TherapyGene Transfer TechniquesHumansIschemiaLymphangiogenesisMicrovesselsNeovascularization, PhysiologicTissue EngineeringTissue ScaffoldsAngiogenesis Inducing Agents

Identifiers

PMID31187896
PMCPMC7025285
OpenAlexW2951573327

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.